4.3 Article

Potentiation of the antitumor effect of calcium phosphate cement containing anticancer drug and caffeine on rat osteosarcoma

期刊

JOURNAL OF ORTHOPAEDIC SCIENCE
卷 16, 期 1, 页码 77-84

出版社

ELSEVIER SCIENCE BV
DOI: 10.1007/s00776-011-0045-3

关键词

-

向作者/读者索取更多资源

Several reports suggest diffusion of anticancer agents from bone cement may suppress tumor growth. New drug delivery systems have been developed that incorporate anticancer drugs into calcium phosphate cement (CPC) to maintain high concentrations of anticancer drugs at local sites. We investigated whether CPC implants containing anticancer drugs and caffeine, which enhance the cytocidal effect of anticancer drugs, would enhance their antitumor effects on rat osteosarcomas (SOSN2 cells). We calculated the release of cisplatin (CDDP) and caffeine from the CPC and bone cement. The following CPCs were prepared: CPC-only, CPC containing caffeine, CPC containing cisplatin, and CPC containing cisplatin and caffeine. We performed cell growth inhibition assays on SOSN2 cells using culture media previously used to incubate each CPC. We transplanted SOSN2 cells into the tibias of rats, excised the tumor 3 days after transplantation, implanted each CPC and observed subsequent tumor growth. The in vitro sustained-release test demonstrated greater amounts and more persistent release of CDDP and caffeine from CPC than from bone cement and also showed CPC could release the majority of its loaded CDDP and caffeine. Culture media containing CDDP and caffeine inhibited in vitro proliferation of SOSN2 cells, and this inhibitory effect was greater than the inhibition resulting from CDDP alone. Experiments with an in vivo rat model demonstrated greater tumor growth inhibition with CPC containing CDDP and caffeine than with CPC containing CDDP alone. The study results suggest CPC containing CDDP and caffeine potentiate antitumor effects and may be effective as a local chemotherapeutic method of treating malignant bone tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Impact of Tumor Growth Speed of Primary Lesions on the Clinical Outcomes of Appendicular Skeletal Metastases

Yohei Asano, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Hirotaka Yonezawa, Yoshihiro Araki, Sei Morinaga, Shiro Saito, Takayuki Nojima, Hiroyuki Tsuchiya

Summary: This study found that appendicular skeletal metastases of primary tumors with rapid growth speed have a higher risk of developing pathological fractures early after the diagnosis of skeletal metastases, and the prognosis may be poor.

ANTICANCER RESEARCH (2022)

Article Oncology

Pretreatment Neutrophil Count and Platelet-lymphocyte Ratio as Predictors of Metastasis in Patients With Osteosarcoma

Yoshihiro Araki, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Hiroyuki Tsuchiya

Summary: This study found that a high platelet-lymphocyte ratio and low absolute lymphocyte count were independent risk factors significantly associated with metastasis in osteosarcoma patients. These findings contribute to the identification of new indicators for predicting metastasis risk in osteosarcoma.

ANTICANCER RESEARCH (2022)

Review Biochemistry & Molecular Biology

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma

Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hiroyuki Tsuchiya

Summary: Chondrosarcomas develop resistance to standard anticancer drugs, making it challenging to control the disease. New treatment approaches, such as molecule-targeting agents and immunotherapy, are needed. Recent studies have identified promising biomarkers and therapeutic targets for chondrosarcoma, and various molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies. This review summarizes recent research on biomarkers and therapeutic targets, as well as clinical studies on the treatment of chondrosarcomas.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Multidisciplinary Sciences

A scoring system combining clinical, radiological, and histopathological examinations for differential diagnosis between lipoma and atypical lipomatous tumor/well-differentiated liposarcoma

Yohei Asano, Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hirotaka Yonezawa, Yoshihiro Araki, Sei Morinaga, Takayuki Nojima, Hiroko Ikeda, Hiroyuki Tsuchiya

Summary: This study evaluated the diagnostic accuracy of various examinations for differential diagnosis between atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLS) and lipoma, and developed a new combined scoring system for preoperative diagnosis. The scoring system based on six predictive factors achieved high diagnostic accuracy without requiring special equipment and reagents.

SCIENTIFIC REPORTS (2022)

Article Oncology

Compartment-specific Clinical Outcomes in Patients With Soft Tissue Sarcomas of the Thigh

Sei Morinaga, Akihiko Takeuchi, Norio Yamamoto, Katsuhiro Hayashi, Shinji Miwa, Kentaro Igarashi, Hirotaka Yonezawa, Yohei Asano, Shiro Saito, Takayuki Nojima, Hiroyuki Tsuchiya

Summary: This study analyzed the relationship between various factors, especially tumor location and clinical outcome, in patients with primary soft tissue sarcoma of the thigh. The results showed that soft tissue sarcomas in the medial compartment were associated with postoperative seroma and metastasis, while sarcomas in the anterior compartment correlated with low postoperative function.

ANTICANCER RESEARCH (2022)

Article Orthopedics

Primary total knee arthroplasty assisted by computed tomography-free navigation for secondary knee osteoarthritis following massive calcium phosphate cement packing for distal femoral giant-cell bone tumor treatment: a case report

Akihiko Takeuchi, Norio Yamamoto, Takaaki Ohmori, Katsuhiro Hayashi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Kensaku Abe, Hirotaka Yonezawa, Sei Morinaga, Yoshihiro Araki, Yohei Asano, Shiro Saito, Hiroyuki Tsuchiya

Summary: Giant cell tumor of bone (GCTB) is an intermediate tumor commonly treated with surgery to preserve the joint. Calcium phosphate cement (CPC) is an artificial bone substitute used for defect adjustment and promoting healing. This study presents a case of secondary osteoarthritis after CPC packing for GCTB curettage that was successfully treated with total knee arthroplasty (TKA) using a computed tomography (CT)-free navigation system.

BMC MUSCULOSKELETAL DISORDERS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

A Viability Analysis of Tumor-Bearing Frozen Autograft for the Reconstruction After Resection of Malignant Bone Tumors Using 99mTc-MDP Scintigraphy

Yoshihiro Araki, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Takayuki Nojima, Junichi Taki, Hiroyuki Tsuchiya

Summary: The viability of devitalized bone grafts in frozen autograft reconstruction after malignant bone tumor excision was evaluated using Tc-99m-MDP scans. The results showed that the viability of bone grafts recovered within 60 months postoperatively, and this method can also predict postoperative complications.

CLINICAL NUCLEAR MEDICINE (2023)

Article Multidisciplinary Sciences

Family cancer history and smoking habit associated with sarcoma in a Japanese population study

Yoshihiro Araki, Norio Yamamoto, Yoshikazu Tanzawa, Takahiro Higashi, Aya Kuchiba, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Makoto Endo, Eisuke Kobayashi, Hiroyuki Tsuchiya, Akira Kawai

Summary: Understanding the etiology, lifestyle epidemiology, and treatment circumstances of sarcoma is crucial for effective prevention and treatment. Research suggests that personal and family cancer history, as well as smoking habit, are associated with the development of certain types of sarcoma.

SCIENTIFIC REPORTS (2022)

Review Oncology

Surgical Site Infection after Bone Tumor Surgery: Risk Factors and New Preventive Techniques

Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hiroyuki Tsuchiya

Summary: Surgical site infection (SSI) is a serious complication in the treatment of malignant bone tumors, adversely affecting functional and oncological outcomes. To improve surgical outcomes, preoperative risk assessments for SSIs, new preventive techniques, and optimal use of prophylactic antibiotics are required.

CANCERS (2022)

Article Oncology

Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: The REALIZE study

Akihiko Takeuchi, Makoto Endo, Akira Kawai, Yoshihiro Nishida, Ryu Terauchi, Akihiko Matsumine, Hisaki Aiba, Tomoki Nakamura, Susumu Tandai, Toshifumi Ozaki, Manabu Hoshi, Daiki Kayano, Miho Okuda, Norio Yamamoto, Katsuhiro Hayashi, Shinji Miwa, Kentaro Igarashi, Kenichi Yoshimura, Akihiro Nomura, Toshinori Murayama, Hiroyuki Tsuchiya

Summary: This study evaluated the safety and efficacy of zaltoprofen in patients with TGCT. There were no significant differences in PFR between the zaltoprofen group and placebo group at 48 weeks. Zaltoprofen treatment significantly improved physical function and was deemed safe for patients.

FRONTIERS IN ONCOLOGY (2022)

Article Cell Biology

A nonsteroidal anti-inflammatory drug, zaltoprofen, inhibits the growth of extraskeletal chondrosarcoma cells by inducing PPARγ, p21, p27, and p53

Takashi Higuchi, Akihiko Takeuchi, Seiichi Munesue, Norio Yamamoto, Katsuhiro Hayashi, Ai Harashima, Yasuhiko Yamamoto, Hiroyuki Tsuchiya

Summary: The nonsteroidal anti-inflammatory drug zaltoprofen induces the expression of PPAR gamma in human extraskeletal chondrosarcoma cells and inhibits their proliferation. Zaltoprofen treatment also inhibits tumor growth and induces tumor cell apoptosis in a mouse model of extraskeletal myxoid chondrosarcoma. These findings suggest the potential use of zaltoprofen as an effective treatment for sarcomas.

CELL CYCLE (2023)

Article Orthopedics

What Are the Complications, Function, and Survival of Tumor-devitalized Autografts Used in Patients With Limb-sparing Surgery for Bone and Soft Tissue Tumors? A Japanese Musculoskeletal Oncology Group Multi-institutional Study

Akihiko Takeuchi, Hiroyuki Tsuchiya, Nokitaka Setsu, Tabu Gokita, Yasunori Tome, Naofumi Asano, Yusuke Minami, Hiroyuki Kawashima, Suguru Fukushima, Satoshi Takenaka, Hidetatsu Outani, Tomoki Nakamura, Satoshi Tsukushi, Teruya Kawamoto, Teruki Kidani, Munehisa Kito, Hiroshi Kobayashi, Takeshi Morii, Toru Akiyama, Tomoaki Torigoe, Koji Hiraoka, Akihito Nagano, Shigeki Kakunaga, Kazuhiko Hashimoto, Makoto Emori, Hisaki Aiba, Yoshikazu Tanzawa, Takafumi Ueda, Hirotaka Kawano

Summary: Tumor-devitalized autografts are a biological reconstruction option that offers advantages such as reduced immunological response, better site match, and no need for a bone bank. However, they also have limitations including inability to assess tumor margins, limited healing potential, and decreased biomechanical strength. Limited data is available on the outcomes of this procedure, making it important for further research.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2023)

Article Oncology

Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis

Yohei Asano, Norio Yamamoto, Satoru Demura, Katsuhiro Hayashi, Akihiko Takeuchi, Satoshi Kato, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Yuta Taniguchi, Sei Morinaga, Takashi Sone, Miho Okuda, Isao Matsumoto, Seiji Yano, Hiroyuki Tsuchiya

Summary: This retrospective study investigated the therapeutic effects of immune checkpoint inhibitors (ICIs) and identified predictors of favorable response and prognosis in advanced non-small-cell lung cancer (NSCLC) patients with bone metastases. The study found a response rate of 30.9% and a median survival time of 9.3 months. Factors such as female sex, use of ICIs as first-line therapy, and pretreatment neutrophil-to-lymphocyte ratio (NLR) less than 2.1 were identified as predictors of therapeutic response, while concomitant use of a bone-modifying agent, Katagiri score <= 6 points, and NLR <2.1 were identified as predictors of good prognosis.

CANCER MEDICINE (2023)

Article Oncology

Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group

Munehisa Kito, Keisuke Ae, Masanori Okamoto, Makoto Endo, Kunihiro Ikuta, Akihiko Takeuchi, Naohiro Yasuda, Taketoshi Yasuda, Yoshinori Imura, Takeshi Morii, Kazutaka Kikuta, Teruya Kawamoto, Yutaka Nezu, Ichiro Baba, Shusa Ohshika, Takeshi Uehara, Takafumi Ueda, Jun Takahashi, Hirotaka Kawano

Summary: This study aimed to analyze the clinical outcomes of patients with low-grade myofibroblastic sarcoma (LGMS). Surgical treatment was the main approach, with radiotherapy considered as a viable option in cases where surgery was not feasible or may cause significant functional impairment.

CANCERS (2023)

Article Pediatrics

Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series

Hisaki Aiba, Michi Kamei, Yasuhiko Ito, Risa Takeda, Satoshi Yamada, Hideki Okamoto, Katsuhiro Hayashi, Shinji Miwa, Yohei Kawaguchi, Shiro Saito, Takao Sakai, Hideki Murakami, Hiroaki Kimura

Summary: This study reports the use of carboplatin as a substitute for cisplatin in the treatment of osteosarcoma, and the efficacy of a CBDCA-based regimen in the neoadjuvant setting was found to be limited. Therefore, it was considered insufficient for performing adequate surgery.

CHILDREN-BASEL (2023)

暂无数据